Podcasts about biotech

What does it look like to take a neuroscience degree far beyond the lab? In this episode, we explore a career path that crosses scientific research, government regulation, and biotech entrepreneurship with Dr. Amanda Wiggins, CEO of The cGP Lab. Amanda began her career investigating neurodegeneration and cortical spreading depression. Over time, her passion for real-world impact led her into public policy—where she helped shape New Zealand's Human Tissue Act and advised on regulations for stem cell research and genetic technologies. Today, she leads a company advancing neuroprotective health supplements based on cyclic Glycine-Proline (cGP), a molecule with growing potential in aging and cognitive health. We talk about: How to navigate transitions between academia, government, and business The challenges of working across disciplines—and how to build confidence in new spaces Lessons learned from leading regulatory change and scaling innovation Amanda's work at The cGP Lab and the science behind cGP's potential in brain health Advice for scientists who want to move into leadership, entrepreneurship, or public engagement This conversation is for anyone considering a non-linear career in neuroscience or wondering how to apply scientific training in new and meaningful ways. Chapters: 00:00:02 - Bridging Neuroscience and Biotech Innovation 00:04:06 - FDA Approval of Trofinetide for Rett Syndrome 00:07:27 - My Journey in Science and Identity 00:09:22 - Pursuing a PhD in Melbourne 00:11:55 - Choosing a PhD Topic 00:17:26 - Challenges and Motivation in PhD Journey 00:20:54 - Transition from Academia to Regulatory Work 00:22:52 - Transitioning from Academia to Policy 00:25:51 - Advising on the Human Tissue Act 00:29:18 - Advocating Biotechnology in New Zealand 00:33:51 - Regulations and Challenges in Biotechnology 00:37:49 - Newborn Blood Screening and Research Ethics 00:41:22 - Transitioning from Science to Biotech 00:46:04 - Challenges of Startup Success 00:48:34 - Journey to Neuroactive Innovation 00:55:23 - Mentorship and Startup Advice 00:58:49 - Dementia Prevention and Early Detection 01:02:03 - Exploring Alzheimer's Research Frontiers 01:06:45 - Advancing Your Neurocareer About the Podcast Guest:

On this week's Tech Nation, Moira speaks with Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider's view of the first real breakthrough in snake antivenom in 125 years, all thanks to a man who's been bitten by over 200 venomous snakes. Then, Robert Blum, CEO of CytoKinetics, shares the latest in hear failure treatment and what it could mean for extending quality of life.

Health Insurance is Rigged & Controlled by the Big Companies w/ Donvan Ryckis of Ethos Benefits   - AZ TRT S06 EP10 (272) 6-15-2025              What We Learned This Week Health Insurance is primarily run by the Big 4 - BUCA: Blue Cross United Healthcare, CIGNA, Aetna To Insurance Co's – Premium = Revenue, and they are not going lower profits, so no incentive to lower costs Health insurance employer group plans can be broken down into 4 Parts Network PPO is what people typically think of when they think of health insurance There have been revisions to the Healthcare Act passed in 2021   Guest: Donovan Ryckis, Ethos Benefits https://ethosbenefits.com/   https://ethosbenefits.com/documentary/ https://businessofbenefitspodcast.com/   Our Ethos is Simple: Fiduciary First. Act in the best interest of those we serve—no matter the cost. ‘Ethos' represents the guiding principle, character, or spirit of a person or organization. It's the ‘why' that drives decision-making and fuel's purpose. Our Ethos is deeply rooted in the story of our Founder, Donovan Ryckis. Over a decade ago, Donovan, a fiduciary Series 65 securities advisor specializing in retirement and pension planning, was approached by a client facing a dire situation. The client's publicly traded broker claimed there was no solution for a staggering 37.5% health insurance renewal increase—a cost that threatened the business and its employees. With no prior experience in health insurance markets but guided by his unwavering fiduciary principles, Donovan took on the challenge. The result? He mitigated the risk entirely, delivering a solution 12% below the current rate. This allowed the business to thrive and ensured hundreds of employees wouldn't have to choose between basic necessities and skyrocketing health premiums. That moment sparked a revelation. The fraud, waste, and abuse Donovan had fought in retirement planning paled in comparison to the challenges in healthcare. He saw an opportunity to bring transparency and fiduciary principles to an industry in desperate need of change. Donovan pivoted his career, becoming one of the first fee-based health insurance advisors in the nation. By removing all conflicts of interest in broker compensation, he laid the foundation for what is now the leading innovative employee benefits agency in the country, delivering higher quality care at a significantly lower cost to employers nationwide.       Notes:   Ethos Benefits deals with employee benefits, with a primary focus on group health insurance   Per Donovan ‘Employee benefits are rigged'   Insurance company premium equals revenue. There is no incentive to lower cost, as it would lower profits.   ACA Obamacare passed in 2010, and it capped profits for insurance companies at 20%   Insurance Co's are working to expand their pool to make more profit   Health Insurance guarantees inflation keeps going up, so family of 4 could spend 35K a year   For a business, healthcare cost and employee benefits are a top 3 P&L expense   Ethos strategies can create a 30 to 40% reduction on premium impact to lower costs for a business   The HQ is in Florida, but they are a virtual office with agents and clients nationwide   Healthcare finance and delivery + Improving employee benefits     Seg 1   Donovan's bio, he was a financial advisor with a Series 65 license before he got into health insurance. Around 2014 he moved into health insurance seeing an opportunity for better service.   Typically you see agents who are working for the health insurance company and not really working for the employer companies they are selling to.   Health insurance is primarily run by the Big 4 – BUCA: Blue Cross United Healthcare, CIGNA, Aetna.   Health insurance employer group plans can be broken down into 4 Parts:   1.    TPA or third-party administrator 2.    Network PPO or HMO 3.    Pharmacy benefit RX 4.    Insurance that covers the caps the limits on the stop loss   PPO is your primary network and open on using referrals HMO is a non-preferred network typically has less offerings and tight on referrals   Ethos Benefits helps employers to break up the four parts of a group plan and customize   Network PPO is what people typically think of when they think of health insurance.   Network and the Big 4 health companies have a tighter deal with doctors and contract prices. A lot is pre-negotiated with a set of rates, which is the point of a PPO. This is where you get larger claims and they run in the system of healthcare.     Seg 2   Pay more for healthcare in the U.S. than the rest of the world   The biggest pharmaceutical companies are in the US Pharmaceutical companies in flight prices, and also set the prices They make money through spread pricing   Employers can actually pick up their own Pharma benefit and get the rebates that the big health insurance companies are not giving them   Healthcare system is a rigged game The fraud waste and abuse extremely high in health   401(k) and retirement benefit industry is actually tighter with more disclosure than the healthcare industry   Regulated better since the creation of the Securities Act in the 1930s and updates that ran through the 1970s and beyond with things like ERISA   There have been revisions to the healthcare act passed in 2021 - started in Jan.2022   Actions had 3 disclosures: ·         Brokers comp and bonus ·         Data with gag, clauses, and full access to data upon request ·         Benchmarking for drug cost     Further Notes via Google:   The revisions you are likely referring to are part of the Consolidated Appropriations Act of 2021 (CAA). While the CAA was passed in late 2020, many of its provisions, including those related to transparency in healthcare, became effective on January 1, 2022.  The three key areas of disclosure you mentioned are directly addressed within these regulations: 1.            Broker's Compensation and Bonuses: The CAA amends ERISA Section 408(b)(2) and requires service providers, including brokers, to disclose specific information to group health plan fiduciaries. 2.            Data Transparency (Gag Clauses and Full Access to Data): The CAA prohibits gag clauses, which prevent plans from providing access to their data. It also requires health insurance carriers to attest annually to their compliance with this prohibition. Moreover, the Health DATA Act, a proposed bill, would further reinforce the right of employers to access their data and hold service providers accountable for non-compliance. 3.            Benchmarking for Drug Costs: The CAA includes provisions regarding pharmacy benefit and drug cost reporting, which aims to provide greater transparency and potentially lead to better benchmarking of drug costs. The Build Back Better Act, a separate piece of legislation, also included provisions for Medicare to negotiate drug prices, further impacting drug costs and potential benchmarking.  These revisions aim to increase transparency in healthcare pricing and empower consumers and employers to make more informed decisions about their healthcare coverage.    Seg 3   Ethos works with Employers to create business plans usually with a 3 to 5 year time horizon. The goal is long-term to lower healthcare cost.   Example would be a company with 100 employees with 50 to 80% of them on the health plan (does not include dependents).   Ethos wants to keep the demands of a company low, easy transition.   Ethos handles employee Qs and healthcare navigation. Ethos is full service.   Risk handled 1 of 4 ways - Reduce, avoid, retain, transfer - Transfer to insurance   Broker wants to transfer risk Company can control costs Careful not to have too much disruption with a switch to a new company   Ex - start with pharmacy part NDC National Drug Code Run report vs costs   Pharmacy benefit mgr   Pre packaged health plan Gets co approved pharmacy benefit Save 5 - 15% on costs (30%)   Separate - parts of group plan     Seg 4   Brokers comp - incentives from big insurance companies   Opening move - edit pharmacy benefit piece   State by state - regulators and rules   Employers / employees Know the network and PPO   Nationwide covers insurance part – Stop-loss Insurance   30-40 major stop loss companies Ex: Allstate Met Life Sun Life   Stop-loss insurance for group health plans acts as a financial safety net for self-funded employers, protecting them from large, unpredictable medical claims. It is a form of additional insurance.   Healthcare risk is incredibly predictable on group basis   Overall predictable w stats, actuarial analysis   Gag clauses look at dataset from current carrier   Prescription database sets   3rd party admin are less of a concern, lots of claims   Average of 18 claims per employee per year, includes dependents   Data - review AI Claims analytics software   AI claims analytics software is transforming how insurance companies handle claims by leveraging artificial intelligence and machine learning to analyze data, automate tasks, and improve decision-making.    30 - 40% reduction in premium w Ethos     Further Notes via Google: Group Medical Plans Breakdown of the common components of a comprehensive employer group health plan, particularly within the context of a self-funded model.  Here's a more detailed explanation of each part: 1.            TPA (Third-Party Administrator): A TPA is a company that provides administrative services for self-funded health plans. This includes processing claims, handling enrollment, and managing other administrative tasks that would typically be done by an insurance company. 2.            Network (PPO or HMO): This refers to the group of doctors, hospitals, and other healthcare providers that the health plan contracts with to provide services to its members. The network defines where employees can go to receive care and often dictates the level of coverage they will receive (e.g., in-network vs. out-of-network benefits). ·                                             PPO (Preferred Provider Organization): Offers more flexibility, allowing members to see out-of-network providers, though with higher out-of-pocket costs. ·                                             HMO (Health Maintenance Organization): Typically requires members to stay within the network for covered services, except in emergencies.                 Pharmacy Benefit (RX): This component manages the prescription drug coverage for the plan. It includes negotiating drug prices, processing claims for prescriptions, and managing the plan's formulary (list of covered drugs).                 Stop-Loss Insurance: This is a crucial element for self-funded employers. It protects the employer from catastrophic claim costs. If an individual employee or the entire group's claims exceed a certain threshold (the "attachment point"), the stop-loss insurance kicks in to cover the excess costs, limiting the employer's financial liability.  Additional Considerations: ·                     Data Access: Self-funded plans often provide employers with greater access to claims data, which can be used to analyze healthcare costs, identify trends, and implement strategies to improve employee health and manage costs. ·                     Benchmarking: Employers can use claims data and industry benchmarks to compare their plan's performance to similar organizations and negotiate better rates with providers and other vendors. ·                     Wellness Programs: Some employers offer wellness programs to encourage employees to adopt healthy behaviors and potentially reduce healthcare costs. ·                     Essential Health Benefits (ACA Compliance): Group health plans must comply with the Affordable Care Act (ACA), which requires them to cover a list of essential health benefits, such as outpatient care, emergency services, hospitalization, and prescription drugs. ·                     Other Benefits: Group plans can also include other benefits, such as dental, vision, life insurance, and long- and short-term disability insurance.  Understanding these different parts is essential for employers to effectively manage their group health plan, control costs, and provide valuable benefits to their employees.      Investing Shows: https://brt-show.libsyn.com/category/Investing-Stocks-Bonds-Retirement       ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

“Every time you think you're right and somebody puts you in your place and you learn from it, eventually you're like, that guy gave me the greatest gift… You learn to love it.” In this episode of The Biotech Startups Podcast, Ivan Liachko, CEO and co-founder of Phase Genomics, delivers an unfiltered look at the realities of building a biotech company, revealing how the mental toll of leadership, managing egos, and embracing frugality shaped his journey from academia to entrepreneurship. Through candid stories of scrappy problem-solving and bootstrapping Phase Genomics, Ivan and host Jon Chee highlight the surprising overlap between science and business, the importance of knowing which game you're playing, and why resilience, adaptability, and learning from failure are crucial for startup success.

Biotech is bursting with innovation—from gene editing to AI-powered diagnostics—but behind every successful breakthrough is something far less talked about: leadership. In this episode of Inside Biotech, we're joined by Colin Smith, CEO and co-founder of ExecNow, a next-gen talent partner helping some of the world's most innovative biotech, greentech, and AI companies find the leaders they need to scale science into sustainable businesses.Colin has spent years working behind the scenes, partnering with founders to solve one of the industry's toughest challenges: bridging the divide between scientific genius and business execution. He shares insights on why many brilliant biotech companies struggle—not because of flawed science, but because they lack the right leadership to guide them through growth, regulation, commercialization, and culture-building.We dive into why the industry struggles to attract diverse and strategic leaders, how values-based hiring makes a difference, and why a clear mission can be a company's strongest competitive advantage. Whether you're a founder, a scientist, or just curious about the human side of biotech, this conversation reveals what it really takes to build companies that not only survive, but lead. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests! To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

  5 Types of Income to Create Infinite Income   - AZ TRT S06 EP09 (271) 5-25-2025              What We Learned This Week Multiple Streams of Income strategy 5 Types of Income – Career, Investment, Retirement Account, Pension, Tax Free Diversification of income provides you security and freedom Build Infinite Income thru initial investment, and profits pay off loans, then go on forever George Lucas created the Star Wars IP one time, and gets infinite returns from the movies & merchandise Real Estate, Business, and Insurance products are good assets for infinite income     Notes:   Segment 1: The 5 Types of Income – Why One Stream Isn't Enough Opening: The Economic Shift ·         The economic landscape has changed dramatically over the last 50 years. ·         While business and technology have advanced, personal finance education and systems haven't kept pace. ·         Inflation has significantly eroded purchasing power. ·         It's no longer the 1950s where one income could support a family of four. Now, two incomes are often required—and even then, many people have a third gig. The New Normal: Side Hustles & Financial Reality ·         According to recent stats, 70% of people need an additional income stream, often from a side business or freelance work. ·         30% of Americans hold a second job. ·         Among millennials, that number rises to 50%.     The Lesson from Robert Allen & Rich Dad, Poor Dad ·         Robert Allen's Multiple Streams of Income advocated for income diversification to gain safety and freedom. ·         Robert Kiyosaki's Rich Dad, Poor Dad emphasized acquiring income-producing assets—his favorite being real estate. The 5 Types of Income 1.    Career or Business Income Your primary, day-to-day W-2 income—pays the bills and covers monthly expenses. 2.    Investment Income Comes from appreciating or income-producing assets like real estate, stocks, or Bitcoin. 3.    Retirement Accounts Tax-deferred income sources like IRAs or 401(k)s—subject to rules and penalties but critical for long-term planning. 4.    Guaranteed Income Comes from pensions, annuities, or Social Security. Designed for lifetime income and stability. 5.    Tax-Free Income Generated through Roth IRAs or cash value from life insurance. You pay tax on the seed, not the harvest. Call to Action: ·         Make a list of which of the five types of income you currently have. ·         Strategize how to build the remaining ones for a balanced, resilient financial future. Analogy: Just like a business has multiple products or a sports team has multiple ways to score, individuals should have diverse income sources to win financially. Segment 2: Infinite Income – Building Streams That Never Run Dry What Is Infinite Income? ·         Infinite income is ongoing, residual income that continues long after the original work or investment. ·         It's the financial holy grail: put in work or money once, get paid over and over. Key Assets That Can Generate Infinite Income: ·         Tangible Assets: Real estate, businesses, stocks ·         Intangible Assets: Skills, knowledge, intellectual property (IP), network Examples of Infinite Income in Action 1. Real Estate ·         Buy a $250K property with 10% down ($25K). ·         Renters pay the mortgage; property appreciates. ·         Refinance later, pull out your original investment tax-free. ·         Continue collecting rental income even after loan is paid off. ·         Use refinance funds to buy more properties → Repeat → Scale. 2. Business Ownership ·         Start or buy a business using a loan. ·         Profits pay off the loan, then continue to generate revenue. ·         Later, use the business as collateral to expand or acquire another. 3. Life Insurance (IUL Strategy) ·         Fund a policy over time; cash value grows tax-deferred. ·         Take loans against the policy tax-free—used as supplemental retirement income. ·         Policy can also be a legacy tool, passing on wealth tax-free. 4. Intellectual Property (IP) ·         George Lucas with Star Wars—created once, profits for decades from merchandise and licensing. ·         Jeff Bezos still profits from Amazon stock, 30 years later. ·         Microsoft, McDonald's, Coca-Cola—IP and systems built once, revenue continues for decades. ·         DC Comics still profiting off Superman IP created in the 1930s. Key Principles for Building Infinite Income ·         Choose the Right Assets: Real estate, businesses, IULs—not just assets that appreciate, but ones that cash flow. ·         Leverage and Scale: Use debt wisely to scale income-producing assets. Wealthy individuals and private equity firms use this strategy constantly. o    Example: PE firms acquire HVAC companies, funeral homes, rental properties—assets that provide consistent 10%+ returns. ·         Use Tax Strategy to Your Advantage: o    Tax-free income is more efficient. o    Lowering your tax burden increases your net income immediately. o    Wealthy individuals use loans, Roths, and life insurance to optimize tax efficiency. Mindset Shift: ·         Don't chase just “buy low/sell high” assets. Instead, acquire harvestable assets—ones that generate regular income and can appreciate. ·         Build cash flow now, use it to reinvest in more assets—repeat the cycle. Closing Thought: ·         Control three things: Assets, Income, Taxes. ·         Master those, and you create not just wealth—but infinite income.     Investing Shows: https://brt-show.libsyn.com/category/Investing-Stocks-Bonds-Retirement       ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Origins hosts Nick Chirls, GP at Asylum Ventures and Beezer Clarkson,  LP at Sapphire Partners and co-founder of OpenLP, unpack their conversation with Zach Weinberg, Co-Founder and CEO of Curie.Bio. They discuss the “innovation energy” that drives new breakthroughs and take a closer look at Sapphire's approach to biotech investing.Learn more about Sapphire Partners: sapphireventures.com/sapphire-partnersLearn more about OpenLP: openlp.vcLearn more about Asylum Ventures: asylum.vcLearn more about Curie.Bio: curie.bioSubscribe to the OpenLP newsletter for a monthly roundup of the latest venture insights, including the newest Origins episodes, delivered straight to your inbox.CHAPTERS:0:00 - Welcome to Origins1:28 -Building Something That Wouldn't Exist Otherwise4:27 - What's Sapphire Doing in BioTech?8:38 - The Market & BioTech10:05 - "Vitamin O"

Join me, Charles River's Miriam Guest, and independent consultant Vanessa Figueroa as we tackle the role of a microbiologist in drug manufacturing. Who is keeping patients safe from contamination, and how are they making sure our life saving drugs are not contaminated? How is manufacturing like yoga? Find out by listening now!

Artificial Intelligence (AI) – how the Algorithm Connects Us All Revisited AZ TRT 2.0 – S06 EP08 (270) 5-11-2025   What We Learned This Week: AI is inter-connected with so many technologies & you use AI often on a daily basis AI is a part of almost all industries from Healthcare, Finance to Defense Human in the Loop - humans will always be needed to Interpret the Data, but AI will assist Software Teams must be managed so the product is integrated properly in the bigger picture   Moore's Law – Each year computing power grows 2x as fast, but cuts the cost in half   Guests: Naru (Narendran Muraleedharan), CEO / Founder of StaxAI – formerly Inventives & Aptus AI https://stax.ai/   linkedin.com/in/naru95       Bio: At Stax.ai, we empower retirement plan TPAs to streamline operations, enhance productivity, and deliver exceptional client experiences. Our innovative platform automates census data collection, payroll integrations, trust accounting, and client communication, all while providing actionable insights through AI-driven tools. Trusted by TPAs managing thousands of plans, Stax.ai transforms administrative burdens into seamless workflows, enabling you to focus on what matters most—growing your business and strengthening client relationships.   Past Bio: Inventives / Aptus AI is a software solutions and artificial intelligence development and consulting firm. They provide aerospace, mechanical, and software engineering services to companies around the world. The Team is strong, and well-rounded consisting of engineers, developers, and physicists that focus on solving problems at the root. They help take ideas or concepts and build prototypes and deployments in very short periods of time with tight budgets while maintaining the best quality and client satisfaction. The main fields of expertise are RPA, Web App Development, Solutions Architecture, Artificial Intelligence, Computer Vision, and Simulation Systems.   Note**: This interview was recorded in Oct. 2021 (S02 EP 43 (90) 10-24-21), since then Naru has changed the company name. Also, the BRT podcast has changed to AZ Tech Roundtable.   Notes: Seg. 2 - 4 Naru returns to the show talking tech, software, and AI. His team is always developing new applications with AI in healthcare, finance, biotech, & aerospace. Naru shows how so many technologies are connected and what the future of business looks like. Inventives is the new company, with the same core technology team, but focusing the business into a venture studio by creating new AI projects for companies not yet using AI. Inventives new projects can become spinoff companies with this new technology.  They work with B2B clients and also Investors for these types of companies.   Radiology is a current project to enhance the patient experience using AI – called SKIP. This project is on the Operations side to make the patient process of paperwork, payments, etc. to be automated (& efficient) with AI working with the patient. This will be stand alone, but if adopted by other medical offices over the long term can streamline the healthcare industry. Naru and his team are working on document management, where their AI program will be able to read documents and determine what the info is. Rising Cloud is another project they are building that manages a company cloud usage to improve costs.   Moore's Law – Each year computing power grows 2x as fast, but cuts the cost in half Cloud Computing happens in the cloud and internet for your programming vs Edge Computing that happens right on your phone and does not need to go out to the cloud. Bigger the data request or process determines if Cloud or Edge is the best choice. People interact with AI (Artificial Intelligence) daily on their phone, email, internet search and beyond. User Agreements in your phone or websites you use say they can take your search data and use it to enhance your experience.   AI Search uses past searches by you, vs what are the popular other searches by other people on the internet. It happens so fast and has the best / popular search options loading before you are even done typing. This is called a Recommendation Engine, just like Netflix or Amazon find shows or products you may like. These recs are similar to what you have watched or bought previously, or in similar genres. The downside is you may not see different options, just more of the same. AI determines what you see daily on the internet, and can create a silo effect. Inventives uses a common solution, called Human in the Loop to review what the AI is doing. Then the searches or recommendations are reviewed to see how accurate they are.  Healthcare AI is assisting doctors, and even finding issues that humans have missed in a radiology study. AI has no bias, and does not get tired. The computer can repeat processes and be consistent.   Key technologies of the day are constantly overlapping – AI, Big Data, Cloud, SaaS Software, etc. This tech can work with each other, and new software can build on top of these applications. Open AI created a product with AI that builds AI software. Naru's Software Teams have different backgrounds of math, engineering or physics who are self taught on software and think more about the solution vs thinking in terms of coding. There are small groups of 2 to 4 people in a team with a Solutions Architect running the small team and determining how the software interacts in the bigger picture. Often some of the best software involved very small teams. Lot of testing and compliance control goes into to creating big software projects that can involve multiple teams. Same issue if building an upgrade to a software that merges with the previous version.   Rewind Clip (Seg. 1) – Replay of a segment from Naru's last appearance on BRT in 11/2020 He talks AI and the morality of the technology. How can a programmer control their product, and what it will be used for in the real world. Naru chose the name Aptus because it is Latin for Apt or Appropriate – design products that works for the clients Chaos Theory / Jurassic Park – Just because you can do it, doesn't mean you should Aptus gets defense contracts as sub-contractor of companies partnered with military. Aptus studies the end applications for what they are requested to build, to determine if they will take the project. Morality is considered, but not always applicable to see where a product may go until it is built. AI software is programmed to build more software, AI building more AI. Per Naru there are companies trying to develop AI weapons that can kill on their own, and robots being controlled by AI already. Aptus has Liability Insurance to protect their projects.       ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT    Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/   Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

睽違半年Happy Hour總算更新啦！這次若晴跟Angel來聊聊最近剛從研討會回來的一些見聞和心得，非常適合搭配上一集新手村005一起收聽！當然我們也不忘Happy Hour的慣例，跟大家分享了一則近期非常振奮人心的客製化基因療法突破的新聞。等待Happy Hour已久的聽眾趕緊收聽吧！ 節目內容： 跟大家更新一下近況 客製化基因療法大突破 芝加哥三腳貓4/6小聚 AACR開幕式小花絮 跟同事學了poster session的搜集資訊的招數 小廢物拿好拿滿還有免費專業大頭照 NIH fellowship小會議見聞 會議結識新朋友的喜悅 -- Hosting provided by SoundOn

John Jannarone joins Diane King Hall to discuss the state of the U.S. IPO market. While he thinks Healthcare and Biotech companies will likely be among the bigger names to go to market, he points to increased activity from Crypto and A.I. companies. Citing a recent banker's meeting, he reveals "the real action is probably in 2026" even following notable IPO's from CoreWeave (CRWV) and Circle (CRCL).======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Bioengineering is a complex field. In some industries it's well established, in others still nascent. But one thing is true regardless of where it's applied – it poses interesting problems. Dr Hamid Noori is one scientist motivated by solving these kinds of big, difficult and (he would say) fun problems. As CEO of bioengineering company, The Cultivated B, his work takes cellular technologies from the lab to the market. On this episode, filmed live at the Rulebreaker Future Congress in Germany, he shares how a grand purpose in life is not necessary if you have audacious problems that you are focused on solving and an openness to solving them in new ways.----------More:Looking Outside podcast www.looking-outside.comConnect with host, Jo Lepore on LinkedIn & X & jolepore.comLearn more about Hamid Noori & Cultivated BFollow Hamid on LinkedIn & his writing on Forbes Technology CouncilFollow Cultivated B on LinkedInCheck out Hamid's other ventures n!Biomachines & PreFerIndustries Learn more on the Rulebreaker Future Congress & the Rulebreaker Society----------⭐ Follow & rate the show - it makes a difference!----------Looking Outside is a podcast exploring fresh perspectives of familiar topics. Hosted by its creator, futurist and strategist, Jo Lepore. New episodes every 2 weeks. Never the same topic.All views are that of the host and guests and don't necessarily reflect those of their employers. Copyright 2025. Theme songs by Azteca X.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Two new members of Kennedy's revamped CDC vaccine advisory committee, Martin Kulldorff and Robert Malone, have a history of being paid expert witnesses in vaccine cases against Merck. They are known for being vaccine skeptics and have questioned the use of mRNA technology in vaccines. Meanwhile, Moderna has received an expanded label for its mRNA RSV shot, but there are concerns about the new ACIP members' questioning of mRNA technology.In other news, Astrazeneca has made a $5.3 billion bet on AI with China's CSPC for chronic disease pills. ADC Therapeutics is cutting staff and closing a research facility, while Biontech has acquired vaccine rival Curevac. The AMA has called for a Senate probe into RFK Jr. after the removal of CDC vaccine advisors.Overall, the industry is facing challenges with layoffs and a tight job market.

Chinese biotech stocks are breaking out—with deals involving Pfizer, Bristol-Myers Squibb, and BioNTech rewriting the playbook for global pharma partnerships. But will the rally last? Back in Singapore, banks like DBS, OCBC, and UOB are buying back shares at scale. And Q&M Dental’s CEO is doubling down on his stock. Plus: Amazon and Walmart explore launching their own stablecoins—could Visa and Mastercard be in trouble? Hosted by Michelle Martin with Ryan Huang, this episode also touches on Novo Nordisk, Oracle, Pop Mart, Emirates, and Jardine Matheson as we unpack the week in markets. Companies mentioned in this episode: Pfizer, Bristol-Myers Squibb, BioNTech, 3SBio, DBS, OCBC, UOB, Q&M Dental, Amazon, Walmart, Visa, Mastercard, Novo Nordisk, Oracle, Pop Mart, Emirates, Jardine Matheson, SATS, SGX.See omnystudio.com/listener for privacy information.

On this week's edition of The New England Business Report, Joe Shortsleeve and Kim Carrigan talk real estate with William Raveis VP of Morguage Lending Kate Rockett. Executive Editor of the Boston Business Journal Doug Banks tell's Joe and Kim all about the International BioTech conference being held in Boston. Mary Kay Wydra, President of Explore Western Mass talks about the great summer activities available to visitors of Western Mass. University of Massachusetts Donahue Institute researcher, Ember Skye Kanelee, summarizes the results of a recent small business survey. Finally, a chat with the CEO of Wears Woody apparel company Mike Norwood. The growing clothing company started in Massachusetts.

Send us a textIn this episode, we sit down with Sonia Gupta, Partner and Co-Head of Biotech Investment Banking at Goldman Sachs. Sonia walks us through her unique journey—from studying public health at Brown, to working in healthcare consulting, to getting her MBA at MIT, and ultimately climbing the ranks at Goldman to become a senior leader advising some of the most innovative biotech companies in the world. We dive deep into what it's like to enter banking post-MBA, how her academic background shaped her approach to the job, and why healthcare—particularly biotech—is such a distinct and intellectually demanding coverage group.We explore the nuances of biotech investment banking: how to value companies that often have no revenue, how the space intersects with venture capital and tech, and why the work often feels more like strategic consulting than traditional M&A. Sonia breaks down the DCF models she and her team build—sometimes stretching 25 years—and the real-life decision-making that goes into supporting clients whose work could lead to the next blockbuster cancer drug or cure for a rare genetic disease. We also talk about how healthcare banking is segmented within the broader investment banking ecosystem and what it really means to be a “coverage banker” at Goldman.Finally, we discuss analyst exit opportunities, how banks like Goldman are thinking about retention, and what it's like building a career—and a family—while advising high-growth companies from San Francisco. Sonia's insights are thoughtful, candid, and inspiring, especially for anyone considering a career in investment banking or healthcare. Whether you're curious about the real-world utility of an MBA, the biotech IPO market, or what it means to grow into true subject matter expertise over time, this episode offers a fascinating window into one of the most complex and purpose-driven sectors on Wall Street.Our Investment Banking and Private Equity Foundations course is LIVEnow with our M&A course included! Shop our LIBRARY of Self Paced Online Courses HEREJoin the Fixed Income Sales and Trading waitlist HERE Our content is for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice.

Karl and Erum speak with Dr. Angela M. Belcher, MIT professor and pioneer in bioinspired materials, about how biology can transform the way we manufacture sustainable technologies. Drawing inspiration from how abalone build shells and viruses assemble structures, Angela shares how her lab uses genetically engineered viruses—like M13 bacteriophage—to grow batteries, solar cells, and cancer-targeting materials at room temperature without harmful chemicals. Her work reimagines the periodic table as a design toolkit and shows how nature's strategies can help us build cleaner, smarter, and more sustainable solutions.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 - Kicking Off with Biology, Innovation & Big Ideas00:00:21 - AI, Simulation Theory & Prompting the Future00:01:57 - Fungi Meets Art: Mycelium's Creative Frontier00:02:44 - Can Synthetic Biology Save the Planet?00:05:54 - Meet Dr. Angela Belcher: Visionary in Biofabrication00:06:29 - Abalone Shells: Nature's Blueprint for Smart Materials00:14:13 - Biotech Meets National Security: A Strategic Frontier00:25:23 - Building Tomorrow's Scientists: Starting with Kids00:26:09 - Sparking Curiosity in the Next Generation00:27:00 - Science in Motion: Dodge Ball & Discovery00:27:53 - Resurrecting the Past: Biodiversity Through Time00:30:01 - Tackling the Grand Challenges in Biomanufacturing00:32:02 - From Bench to Nation: Scaling U.S. Biotech00:36:03 - Mining, Carbon & Clean Tech: A Greener Path00:38:42 - The Future of Biofabrication: What Comes Next?00:40:53 - Angela's Journey: Curiosity, Grit & What's Ahead00:43:32 - Final Reflections: Science, Society & What Matters MostLinks and Resources:⁠NSCEBNSCEB REPORT: Charting the Future of Biotechnology GenspaceBen Lamm on Joe Rogan ExperienceScientists use synthetic biology to address urgent sustainability challengesThe Age of Living Machines by Susan Hockfield⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: biomanufacturing, cell free biomanufacturing, enzymes, nutraceuticals, biotech, pharmaceuticals, AI, spinoutsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Send us a textDaniel Tabb brings over 15 years of experience in the insurance industry, specializing in working with Life Science companies ranging from pre-seed startups to publicly traded corporations. As a leader of the Life Science Practice at Houchens Insurance Group, Daniel possesses a deep understanding of the unique risks and challenges faced by life science companies in today's dynamic environment.00:00 Introduction to Life Science Success Podcast00:29 Meet Daniel Tabb: Life Sciences Insurance Expert01:26 Daniel's Journey into the Insurance Industry03:32 Specializing in Life Sciences05:09 Key Career Transition Points12:06 Understanding Life Sciences Insurance15:49 Unique Risks and Challenges in Life Sciences18:23 Innovative Projects and Future of Insurance24:17 Leadership and Personal Insights33:49 Conclusion and Final Thoughts

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Philipp Vetter über die Folgen des Air-India-Absturzes für Boeing, den steigenden Goldpreis aus Angst vor einem Iran-Krieg und starke Cloud-Zahlen von Oracle. Außerdem geht es um SAP, Palantir, Deutsche Telekom, Boeing, MTU Aero Engines, T-Mobile US, Biontech, Curevac, Bristol-Meyer Squibb, PTT PCL, DBS Group, Singapore Exchange, Xtrackers MSCI Thailand (WKN: DBX0GY), UBS MSCI Singapore (WKN: A14MF5), Xtrackers MSCI Singapore (WKN: DBX0KG), Franklin FTSE Asia ex China ex Japan (WKN: A2JKU). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC has reinstated around 460 employees who were previously fired, with the rehired staff working on viral disease prevention efforts and sexual health testing labs. This comes amid protests and shake-ups at the agency, including the overhaul of the vaccine advisory committee. Experts are concerned about newly appointed members, some of whom are known anti-vaxxers, potentially relitigating recommendations. Sen. Bill Cassidy is being urged to step up in response to these concerns.In other news, NuVation has received FDA approval for its oral lung cancer drug, Biontech has acquired CureVac in a $1.25 billion all-stock deal, and RFK Jr. has named new CDC vaccine advisors following a "clean sweep." Additionally, InVitro Cell Research is focused on discovering interventions to slow aging and prevent age-related diseases and is hiring scientists. The newsletter also includes information on layoffs at Genentech and Vertex.RFK Jr. has named eight new members to the CDC vaccine committee, replacing the 17 members he removed earlier in the week. The new choices seem to align with Kennedy's anti-vaccine views, causing concern among analysts. The HHS secretary's decision to appoint these scientists has raised questions about the committee's future direction.

Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of that figure. Not surprising when you think that healthcare focused biotech companies are battling to solve some of our biggest health concerns; turning an ageing society into a longevity society by supporting longer and healthier lives. In this episode of The Next Five, Paul Little, CEO of Vesper Bio discusses frontotemporal dementia and the impact of it on human health and society, the biotech solutions being sort to combat the disease as well as what he describes as a Malthusian crisis around biotech funding. Dr Ann Beliën, Founder and CEO of Rejuvenate Biomed addresses the problems of Sarcopenia as well as the biotech solutions for it and how Biotech companies use creative ways to secure funding. Gianmario Verona, President of Human Technopole, highlights the importance of industry collaboration and how innovation centres can help propel the biotech sector forward. Sources: FT Resources, WHO, JP Morgan, Alzheimersresearchuk, IQVIA This content is paid for by Yes Milano and is produced in partnership with the Financial Times' Commercial Department. Hosted on Acast. See acast.com/privacy for more information.

Chaque jour, découvrez la pépite du jour dans la France Bouge avec Elisabeth Assayag. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Plus: Oracle posts strong quarterly results boosted by its AI investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting higher-than-expected earnings. Ariana Aspuru hosts.  Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The chaos Trump is creating in Southern California is a distraction from the other cruel, careless, and destructive actions of his administration. The assault on higher education and Harvard University in particular will cost us enormously, especially in terms of medicine and science. Here's my 2012 conversation with Don Ingber, founding director of Harvard's Wyss Institute for Biologically Inspired Engineering, who has emerged as one of the leading voices defending science and attacking White House cuts to research. Following this conversation you're about to hear, I was hired by the Wyss Institute to host and co-produce Disruptive, a 17 episode podcast series, honored by the Webbies as one of the five top science podcasts of 2017. Search Disruptive, Terrence McNally to find the series at numerous sites.

What happens when a retired-at-38 scientist turns a crowdfunding platform into one of the most predictive biotech VC machines on the planet? In this high-voltage episode of 9x90™, Adi Soozin interviews Alex Fair, founder of MedStarter, a medtech and biotech fund redefining early-stage investing. With a 44% IRR, MedStarter's data-driven approach—built on founder psychometrics, expert networks, and founder grit—has funded companies that now move billions and influence healthcare policy.Alex reveals the secrets behind Fund III, their $40M accelerator-backed investment vehicle designed to identify 130 future game-changers before they hit mainstream. You'll also get a rare look into the elite salons where billionaires, policy-makers, and innovation freaks collaborate, and how “Dinner with the Winners” is helping surface the next great unicorns.Whether you're an LP looking for alpha, a founder with something to prove, or a connector seeking the next wave of disruptors—this is the episode you don't want to miss.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The American Medical Association is calling for a Senate probe into RFK Jr. after he removed all 17 members of the CDC's vaccine advisory board. They are also urging an immediate reversal of the HHS Secretary's decision. In other news, FDA leaders promise support for gene therapy as it faces challenges, Novo Nordisk invests over $800 million in discovering oral obesity drugs, and a new company, InVitro Cell Research, focuses on interventions to slow aging and prevent age-related diseases. FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article outlining the FDA's priorities, including accelerating cures and deploying artificial intelligence quickly. Other news includes Lilly's muscle-preserving treatment pact, Vertex laying off staff after axing a diabetes asset, and Genentech reshuffling in South San Francisco. Recursion cuts workforce by 20%.FDA leaders have pledged support to gene therapy makers as the industry faces challenges in commercialization. Despite huge valuations, gene therapies are struggling to reach the market. Poor communication about the value of groundbreaking treatments is hindering their prospects. Right of first negotiation deals do not always lead to mergers and acquisitions, as found by Jefferies in their analysis of licensing deals. Trilink's new comprehensive IVT kit simplifies the production of mRNAs. In other news, Lilly strikes a $650 million deal for a muscle-preserving treatment, Odyssey ends its quest for Nasdaq, BMS expands its radiopharma presence, and SpliceBio secures $135 million in funding for protein splicing medicines. Novo ups its obesity efforts with an $800 million pact, while Cullinan makes a $700 million deal for autoimmune T cell engager in China.Thank you for listening to Pharma and Biotech Daily.

US equity-index futures dipped along with the dollar after President Donald Trump said he will set unilateral tariff rates within two weeks, dialing up trade tensions once again. The comments come a day after Chinese and US officials struck a positive tone following their talks to dial down trade tensions. Amid US talking with countries including India and Japan to lower the levies, some investors see Trump's comments as an effort to ramp up urgency in talks. We talk markets with Zachary Hill, Head of Portfolio Management at Horizon Investments. Plus - China's biotech industry is gaining momentum, with Pfizer and Bristol-Myers Squibb making billion-dollar deals with Chinese companies to license experimental cancer drugs. The industry is expected to continue growing, driven by factors such as US President Donald Trump's economic policies, cheaper and easier human testing in China, and an abundance of young and affordable engineering talent. We check in with Shuli Ren, Bloomberg Opinion Columnist, for a closer look at the sector.See omnystudio.com/listener for privacy information.

Hace dieciséis años, Albert Jané y Òscar Expósito transformaron un laboratorio universitario en el punto de partida de un proyecto con una visión clara: unir ciencia y naturaleza para crear una nueva forma de entender la cosmética. Vytrus Biotech, nació en 2009, en la Facultad de Farmacia de la Universidad de Barcelona, con el objetivo de trasladar el conocimiento científico al sector cosmético mediante una propuesta diferencial e innovadora. Hoy en empresas cotizadas, Jordi Rovira, CFO y Miembro del Consejo de Administración de Vytrus Biotech, nos habla de la historia de la empresa, así como su presente y su futuro. En 2011, Vytrus logró un hito relevante en el ámbito nacional. La creación del primer ingrediente cosmético basado en células madre vegetales desarrollado en España. Este avance, junto con la confianza de los primeros inversores, permitió establecer las primeras instalaciones y unidades de producción. Entre 2013 y 2018, la compañía consolidó su proyección internacional. La biotecnología verde de Vytrus comenzó a integrarse en formulaciones cosméticas en Europa, Asia, América y Oceanía. Actualmente, sus ingredientes están presentes en más de 42 países. En marzo de 2022, otro hito marcó su trayectoria: la compañía comenzó a cotizar en el mercado BME Growth, especializado en pequeñas y medianas empresas con alto potencial de crecimiento. Este paso reforzó su compromiso con la transparencia, la sostenibilidad y la innovación. De cara a este año 2025, el invitado se muestra positivo, y a pesar de haber firmado un arranque de año excepcional, con una subida del 83% en el BME Growth, Jordi asegura que “confiamos en que el siguiente trimestre, el crecimiento sea superior”. Para ello, afirma medidas como duplicar la apuesta inversora para expandir la capacidad productiva”.

Biontech kauft seinen Konkurrenten Curevac 1,25 Milliarden Dollar. Und: Brainlab kündigt Deutschland größten IPO an. Erwartet wird eine Bewertung von rund zwei Milliarden Euro.

What if the culture you're building is quietly holding back top talent? In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, sit down with Carlo Odicino, MBA—Founder and CEO of One Team Partners—to explore how unconscious gender bias affects team dynamics, pay equity, and innovation in biotech startups. Drawing from his experience working with high-growth companies, Carlo shares real-world insights and practical tools for identifying bias and fostering intentional, inclusive workplace cultures. In this episode, you'll discover: How unconscious bias manifests in hiring, performance reviews, and leadership interactions. Strategies startups can use to identify pay gaps, support equitable leadership, and create feedback-safe environments. Why inclusive culture isn't a “later” priority—and how getting it right early can reduce turnover and accelerate growth. From subtle labels like “bossy” to structural decisions that perpetuate inequity, this episode offers clear-eyed advice for founders and executives ready to build better biotech companies. Links: Connect with Carlo Odicino, MBA, and check out One Team Partners. Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

What happens when a scientist becomes a VC? We sat down with Madrona's Joe Horsman to find out. In this episode, Joe shares his journey from late nights in the lab to helping biotech founders bring life-changing science to market. You'll hear: Why Seattle's biotech + AI ecosystem is heating up What founders need beyond funding to commercialize world-changing science. Why weekend adventures fuel Monday creativity

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.

In this episode of Careers in Discovery, we're joined by Markus Gruell, Senior Vice President of Corporate Quality at Autolus, one of the UK's leading CAR-T therapy pioneers. Markus takes us behind the scenes of Autolus' journey from a UCL spinout to a commercial-stage Biopharma company, offering a rare look at how quality underpins every part of the drug development lifecycle. From working across GMP and GCP to collaborating with regulators on novel therapies, Markus shares what it means to lead quality in a fast-moving, high-growth Biotech business. We also explore Markus' personal journey - from pharmacist to QP, and from the NHS to senior leadership - guided by a passion for learning, a commitment to patient safety, and a belief in empowering his team through empathy and integrity. If you're curious about CAR-T, what quality looks like in a next-gen therapy company, or how to build a meaningful leadership career without a traditional plan, this episode is not to be missed.  

To Sign up for our Patreon go to-> Patreon.com/cultofconspiracypodcast10% OFF Rife Machine---> https://rifemachine.myshopify.com/?rfsn=7689156.6a9b5cMeta Mysteries Podcast---> https://open.spotify.com/show/6IshwF6qc2iuqz3WTPz9Wv?si=3a32c8f730b34e79http://Brogrove.comCajun Knight Youtube Channel---> https://www.youtube.com/@Cajunknight50% OFF Adam&Eve products---> :adameve.com (promo code : CULT)10%OFF Orgonite ! ---> https://oregon-ite.com/?sca_ref=5029405.hji3fNHxUdTo Sign up for our Rokfin go to --> Rokfin.com/cultofconspiracyBecome a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if we could rewrite the code of life—just like editing a Word doc?Gene-editing pioneer David Liu takes us behind the scenes of the revolutionary tools transforming medicine. He's the Harvard scientist who invented base editing—a breakthrough that lets scientists fix a single DNA letter to correct genetic disease at its root.This is science fiction come to life—and it's happening now. He edits DNA like we edit text. Come meet the man who's changing lives, one letter at a time. 

Explore the science behind genetically engineered probiotics with Zack Abbott, PhD of ZBiotics. We talk about hacking gut bacteria to reduce hangovers and turn sugar into fiber—plus why bacterial diversity is key to better health. Lindsey Parsons, your host, helps clients solve gut issues and reverse autoimmune disease naturally. Take her quiz to see which stool or functional medicine test will help you find out what's wrong. She's a Certified Health Coach at High Desert Health in Tucson, Arizona. She coaches clients locally and nationwide. You can also follow Lindsey on Facebook, Tiktok, X, Instagram or Pinterest or reach her via email at lindsey@highdeserthealthcoaching.com to set up your free 30-minute Gut Healing Breakthrough Session. Show Notes

Darshan's LinkedIn: https://www.linkedin.com/in/darshankulkarni/Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

BeyondGREEN Biotech: Revolutionizing Sustainable Products with Family Values Byndgrn.com About the Guest(s): Rudy Patel is the Chief Marketing Officer at Beyond Green Biotech Incorporated, a pioneering company in the sustainable alternatives to single-use plastics industry. Launched in 2016 alongside his father and brother, Rudy has played a pivotal role in transforming the company from a garage startup into a substantial US manufacturing operation. Beyond Green Biotech is notable for its commitment to environmental sustainability, focusing on innovations such as resin production, extrusion converting, and fulfillment. Rudy is dedicated to combating issues like greenwashing by offering transparency and eco-friendly products. Episode Summary: Dive into the world of sustainability with The Chris Voss Show, where host Chris Voss engages with Rudy Patel, the dynamic CMO of Beyond Green Biotech Incorporated. This episode unravels the journey and growth of a company dedicated to creating sustainable solutions to replace single-use plastics. Rudy shares their initial inspiration, driven by a family legacy aims to rectify environmental missteps with progressive, eco-friendly products. The conversation also presents insights into working in a family business and the importance of aligning company values with sustainable practices. In this enlightening episode, discover how Beyond Green Biotech is fighting the battle against greenwashing and leading a transparent revolution in compostable goods. Rudy elaborates on how the company emphasizes authenticity, with advice on verifying green certifications and avoiding misleading eco-friendly claims. With a global vision for expansion, the episode touches on the company's strategy for branding through product placement, green tech innovation, and continued partnerships with giants like Walmart. This conversation is not just about green products; it's about building community, enduring persistence, and fostering a company culture steered towards a better planet. Key Takeaways: Transparency in Sustainability: Beyond Green Biotech stresses the importance of verifying authentic green certifications to combat greenwashing. Business Growth and Challenges: Rudy shares insights on growing a business collaboratively with family, highlighting persistence and passion as key elements of success. Innovative Product Development: The company's range extends beyond pet products to include contributions to major retailers, showcasing their ability to scale and customize solutions. Vision for a Greener Future: Beyond Green is dedicated to not just sustainable products but also to devising the entire life cycle and disposal systems, advancing green tech and software initiatives. Community and Family in Business: The company thrives on strong team dynamics, treating team members like family to drive their mission forward. Notable Quotes: "Believe in your mission, believe in yourself. And if you break down, that's okay. Get back up the next day and keep going." "Greenwashing is essentially falsified plastic products that have chemicals added… they're not actually compostable." "Our job is to make the entire environment easier for our users." "The consumer should not have to think twice…we have great partnership with our suppliers." "We didn't build a team with Beyond Green. We built a family and this family is helping give back to the community."

We love to hear from our listeners. Send us a message. On this week's episode, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere.   This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

"Passion is chaos. You're doing unreasonable things sometimes for reasons you can't explain to anyone why. That's just what I want.” In this episode of The Biotech Startups Podcast, host Jon Chee sits down with Ivan Liachko, CEO and co-founder of Phase Genomics, to reveal how a childhood passion for genetics, relentless family support, and Ivan's trademark persistence—“better to be annoying than forgotten”—helped him break into science as an immigrant and rise to biotech leadership. Ivan shares candid lessons on embracing unpredictability, turning setbacks into opportunities, and the parallels between research and entrepreneurship, emphasizing the power of authentic curiosity, running toward problems, and leading with bold optimism.

In this bite-sized H-Files episode, I unpack 5 hard-won lessons from my conversation with Nigel Theobald, CEO of N4 Pharma.After a decade of building a biotech platform for RNA delivery, Nigel knows exactly how brutal, and how rewarding this space can be.You'll walk away with:The one sentence every founder must write downWhy you can't bootstrap biotechHow to pivot with purposeThe truth about investor trustAnd why execution matters more than competitionHit play and take notes. Your future self will thank you.

Ever wondered what makes your brain so incredibly complex, or what happens when things go wrong? Join us for this tiny expedition as we demystify brain health and disease, breaking down the intricate cellular makeup of the brain and its vital functions. You'll learn about the spectrum of brain diseases and disorders and how ongoing research is transforming our understanding of these often devastating diseases.To go behind the scenes and learn more about this episode, visit “Brain Health: What happens when things go wrong?”Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

An M&A wave is coming in biotech. Plus, the U.S. vs. China: Who needs a deal more? … The Fed's B.S. move… Time to buy small caps? … Buy these cryptos… And the next CoreWeave (CRWV)? In this episode: The NHL Stanley Cup: Which team I'm rooting for [0:33] Should investors "sell in May and go away"? [4:31] The U.S. vs. China: Who needs a deal more? [9:15] I agree with Senator Warren about this Fed move [16:24] Is it time to buy small caps? [24:12] A regional bank for your watchlist [25:01] Why biotech is about to see M&A heat up [28:13] Will Robinhood be the next S&P 500 stock? [39:36] Buy these cryptos for the next bull market [41:51] Why CoreWeave keeps surging higher [44:04] Is this IPO the next CoreWeave? [51:23] Did you like this episode? Get more Wall Street Unplugged FREE each week in your inbox. Sign up here: https://curzio.me/syn_wsu Find Wall Street Unplugged podcast… --Curzio Research App: https://curzio.me/syn_app --iTunes: https://curzio.me/syn_wsu_i --Stitcher: https://curzio.me/syn_wsu_s --Website: https://curzio.me/syn_wsu_cat Follow Frank… X: https://curzio.me/syn_twt Facebook: https://curzio.me/syn_fb LinkedIn: https://curzio.me/syn_li

近十年来，中国的创新药行业经历了「过山车式」的发展。2015年的药政改革和随之而来的资本助推，让中国的 biotech 呈爆发式的增长，截至2023年，中国创新药企的数量已经从个位数增长到了超过 1000 家，在多个创新药赛道都取得了突破性的进展。而然最近三年，随着资本回归理性，创新药企也遭遇了前所未有的危机，不少 biotech 以对外授权 （License-out）的形式向国外大药企出售自己的产品，也有不少中国药企选择出海。 跨国药企在中国疯狂扫货背后的动机是什么？中国的新药管线为何物美价廉？中国的 biotech 是否有机会成长为全球性的 biopharma？本期节目，我们请到两位在中美两国都有丰富工作经验的医药投资人和创业者，与大家聊一聊中国创新药企在资本寒冬下正在经历的危机与未来发展的挑战。 本期节目与生物医药类播客《ATGC Doctors' Chat》 (https://www.xiaoyuzhoufm.com/podcast/629dffbb66194a288c699cdc)联合制作，欢迎订阅，获取更多关于生命科学、医药投资与前沿科技的深度对话： 主要话题 [03:02] 资本寒冬的另一面：跨国药企在中国疯狂买买买 [07:16] 外企来华扫货，中国资产为什么又好又便宜？ [12:14] 从 biotech 到 biopharma，重磅产品、商业化能力、领导团队缺一不可 [15:42] 中国 biotech 能否复制日本药企的成功路径？ [20:59] 如何找到重磅药物? Blockbuster 可遇而不可求的 [27:31] 传统药企的艰难转型：同样是卖药，卖仿制药和创新药有何区别？ [34:46] 展望未来：AI 在医药行业的必然角色 补充内容：《血色财富》抗癌新药背后的阴谋、信念与梦想 (https://www.xiaoyuzhoufm.com/episode/676022677d8426f6928f87bb) 蔡司睐光 2.0 渐进镜片 近视又老花，蔡司有办法！蔡司睐光 2.0 渐进镜片，是初次配戴渐进镜片的理想之选，蔡司深度理解眼睛结构和用眼需求，让渐进镜片符合眼睛运动轨迹，从容切换近远视距，享受品质生活的每一秒。选择蔡司渐进镜片，让清晰视界，点亮你的工作与生活，实现视野自由！关注“卡尔蔡司光学”微信公众号查看产品详情 Untitled https://media24.fireside.fm/file/fireside-uploads-2024/images/4/4931937e-0184-4c61-a658-6b03c254754d/x8kmsYUR.png 本期人物 Yaxian, 「科技早知道」节目监制，「ATGC doctors' chat」主播 钟琇，「ATGC doctors' chat」主播 舒骁， 盛鼎医药投资创始合伙人 李铭曦， 上海湃隆生物科技有限公司 CEO 延伸阅读 Biotech（生物科技公司） 指专注于生物技术研发的创新型企业，通常规模较小，以科研和早期药物开发为核心。 Pharma（大型制药公司） 如辉瑞（Pfizer）、默克（Merck）等，拥有完整研发、生产及商业化能力的跨国药企。 BD（Business Development，商业拓展） 包括授权交易（License-in/out）、并购等商业合作，例如中国Biotech向海外药企授权管线。 ADC（Antibody-Drug Conjugate，抗体偶联药物） 通过抗体靶向递送细胞毒性药物的技术，近年成为研发热点。 Blockbuster（重磅药物） 年销售额超过10亿美元的药物（如PD-1抑制剂、GLP-1类药物） 幕后制作 监制：Yaxian 后期：迪卡 运营：George 设计：饭团 加入声动活泼 声动活泼目前开放全职设计师、商业发展经理、商业内容策划、内容编辑实习生、早咖啡内容研究实习生、社群运营实习生等6个职位，详情点击招聘入口 (https://eg76rdcl6g.feishu.cn/docx/XO6bd12aGoI4j0xmAMoc4vS7nBh?from=from_copylink) 商务合作 声动活泼商务合作咨询 (https://sourl.cn/6vdmQT) Untitled https://media24.fireside.fm/file/fireside-uploads-2024/images/4/4931937e-0184-4c61-a658-6b03c254754d/G8JTHkTU.png 关于声动活泼 「用声音碰撞世界」，声动活泼致力于为人们提供源源不断的思考养料。 我们还有这些播客：声动早咖啡 (https://www.xiaoyuzhoufm.com/podcast/60de7c003dd577b40d5a40f3)、声东击西 (https://etw.fm/episodes)、吃喝玩乐了不起 (https://www.xiaoyuzhoufm.com/podcast/644b94c494d78eb3f7ae8640)、反潮流俱乐部 (https://www.xiaoyuzhoufm.com/podcast/5e284c37418a84a0462634a4)、泡腾 VC (https://www.xiaoyuzhoufm.com/podcast/5f445cdb9504bbdb77f092e9)、商业WHY酱 (https://www.xiaoyuzhoufm.com/podcast/61315abc73105e8f15080b8a)、跳进兔子洞 (https://therabbithole.fireside.fm/) 、不止金钱 (https://www.xiaoyuzhoufm.com/podcast/65a625966d045a7f5e0b5640) 欢迎在即刻 (https://okjk.co/Qd43ia)、微博等社交媒体上与我们互动，搜索 声动活泼 即可找到我们。 期待你给我们写邮件，邮箱地址是：ting@sheng.fm 声小音 https://files.fireside.fm/file/fireside-uploads/images/4/4931937e-0184-4c61-a658-6b03c254754d/gK0pledC.png 欢迎扫码添加声小音，在节目之外和我们保持联系。 Special Guests: 李铭曦, 舒骁, 钟琇, and 雅娴.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.